

Giulia Martina Cavestro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8113612/publications.pdf>

Version: 2024-02-01

92
papers

8,319
citations

136950

32
h-index

48315

88
g-index

94
all docs

94
docs citations

94
times ranked

9187
citing authors

#	ARTICLE	IF	CITATIONS
1	Advanced Techniques in Colonoscopy in Inherited Cancer Conditions. , 2022, , 471-483.		0
2	Transoral incisionless fundoplication with Medigus ultrasonic surgical endostapler (MUSE) for the treatment of gastro-esophageal reflux disease: outcomes up to 3Åyears. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 5023-5031.	2.4	3
3	Diet and Lifestyle Habits in Early-Onset Colorectal Cancer: A Pilot Case-Control Study. Digestive Diseases, 2022, 40, 710-718.	1.9	5
4	HLA-DRB1âˆ™16 and -DQB1âˆ™05 alleles are strongly associated with autoimmune pancreatitis in a cohort of hundred patients. Pancreatology, 2022, 22, 466-471.	1.1	3
5	Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Journal of Medical Genetics, 2021, 58, 369-377.	3.2	31
6	Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the Lynch syndrome tumor spectrum. International Journal of Cancer, 2021, 148, 512-513.	5.1	9
7	Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. Genetics in Medicine, 2021, 23, 705-712.	2.4	28
8	Advanced Techniques in Colonoscopy in Inherited Cancer Conditions. , 2021, , 1-13.		0
9	Genomeâ€wide scan of long noncoding <scp>RNA</scp> single nucleotide polymorphism<scp>s</scp> and pancreatic cancer susceptibility. International Journal of Cancer, 2021, 148, 2779-2788.	5.1	23
10	Impaired exocrine pancreatic function in different stages of type 1 diabetes. BMJ Open Diabetes Research and Care, 2021, 9, e001158.	2.8	13
11	Long-term outcomes of transoral incisionless fundoplication for gastro-esophageal reflux disease: systematic-review and meta-analysis. Endoscopy International Open, 2021, 09, E239-E246.	1.8	24
12	Low-frequency of RABL3 pathogenetic variants in hereditary and familial pancreatic cancer. Digestive and Liver Disease, 2021, 53, 519-521.	0.9	2
13	Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Scientific Reports, 2021, 11, 7570.	3.3	2
14	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. Journal of Clinical Medicine, 2021, 10, 2856.	2.4	11
15	Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Carcinogenesis, 2021, 42, 1037-1045.	2.8	14
16	Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Frontiers in Genetics, 2021, 12, 693933.	2.3	10
17	Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2342-2345.	2.5	4
18	The Role of Diet and Lifestyle in Early-Onset Colorectal Cancer: A Systematic Review. Cancers, 2021, 13, 5933.	3.7	22

#	ARTICLE	IF	CITATIONS
19	Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. <i>Genetics in Medicine</i> , 2020, 22, 15-25.	2.4	365
20	MSH6 gene pathogenic variant identified in familial pancreatic cancer in the absence of colon cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 345-349.	1.6	5
21	Analysis of GPRC6A variants in different pancreatitis etiologies. <i>Pancreatology</i> , 2020, 20, 1262-1267.	1.1	1
22	Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database. <i>Journal of Clinical Medicine</i> , 2020, 9, 2290.	2.4	12
23	Oral and Fecal Microbiota in Lynch Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 2735.	2.4	10
24	Decline in the incidence of colorectal cancer and the associated mortality in young Italian adults. <i>Gut</i> , 2020, 69, 1902-1903.	12.1	9
25	Genome-wide association study identifies an early onset pancreatic cancer risk locus. <i>International Journal of Cancer</i> , 2020, 147, 2065-2074.	5.1	20
26	Early-onset colorectal cancer: trends and challenges. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 491-492.	8.1	6
27	Common variants in glyoxalase I do not increase chronic pancreatitis risk. <i>PLoS ONE</i> , 2019, 14, e0222927.	2.5	0
28	Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. <i>Carcinogenesis</i> , 2019, 40, 544-550.	2.8	8
29	Germline <i>BRCA2</i> K3326X and <i>CHEK2</i> I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2019, 145, 686-693.	5.1	20
30	Association of Polyps with Early-Onset Colorectal Cancer and Throughout Surveillance: Novel Clinical and Molecular Implications. <i>Cancers</i> , 2019, 11, 1900.	3.7	9
31	Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. <i>International Journal of Cancer</i> , 2019, 144, 1275-1283.	5.1	36
32	Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Registry. <i>American Journal of Gastroenterology</i> , 2019, 114, 665-670.	0.4	35
33	Colorectal cancer screening from 45 years of age: Thesis, antithesis and synthesis. <i>World Journal of Gastroenterology</i> , 2019, 25, 2565-2580.	3.3	46
34	Early onset sporadic colorectal cancer: Worrisome trends and oncogenic features. <i>Digestive and Liver Disease</i> , 2018, 50, 521-532.	0.9	65
35	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nature Communications</i> , 2018, 9, 556.	12.8	188
36	Genome-wide association study identifies inversion in the <i>CTRB1-CTRB2</i> locus to modify risk for alcoholic and non-alcoholic chronic pancreatitis. <i>Gut</i> , 2018, 67, 1855-1863.	12.1	97

#	ARTICLE	IF	CITATIONS
37	Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. <i>International Journal of Cancer</i> , 2018, 142, 290-296.	5.1	14
38	Common variants in the CLDN2-MORC4 and PRSS1-PRSS2 loci confer susceptibility to acute pancreatitis. <i>Pancreatology</i> , 2018, 18, 477-481.	1.1	14
39	Meta-analysis of the impact of SPINK1 p.N34S gene variation in Caucasian patients with chronic pancreatitis. An update. <i>Digestive and Liver Disease</i> , 2017, 49, 847-853.	0.9	20
40	Low Alcohol and Cigarette Use Is Associated to the Risk of Developing Chronic Pancreatitis. <i>Pancreas</i> , 2017, 46, 225-229.	1.1	8
41	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. <i>Oncotarget</i> , 2016, 7, 66328-66343.	1.8	88
42	Pancreatic morpho-functional imaging as a diagnostic approach for chronic asymptomatic pancreatic hyperenzymemia. <i>Digestive and Liver Disease</i> , 2016, 48, 1330-1335.	0.9	13
43	Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. <i>Oncotarget</i> , 2016, 7, 57011-57020.	1.8	41
44	A single-centre prospective, cohort study of the natural history of acute pancreatitis. <i>Digestive and Liver Disease</i> , 2015, 47, 205-210.	0.9	38
45	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. <i>Nature Genetics</i> , 2015, 47, 911-916.	21.4	224
46	Polymorphisms at PRSS1-PRSS2 and CLDN2-MORC4 loci associate with alcoholic and non-alcoholic chronic pancreatitis in a European replication study. <i>Gut</i> , 2015, 64, 1426-1433.	12.1	105
47	Pancreatic abnormalities detected by endoscopic ultrasound (EUS) in patients without clinical signs of pancreatic disease: Any difference between standard and Rosemont classification scoring?. <i>Pancreatology</i> , 2014, 14, 227-230.	1.1	13
48	Outcome of endotherapy for pancreas divisum in patients with acute recurrent pancreatitis. <i>World Journal of Gastroenterology</i> , 2014, 20, 17468.	3.3	36
49	Classification of acute pancreatitis 2012: revision of the Atlanta classification and definitions by international consensus. <i>Gut</i> , 2013, 62, 102-111.	12.1	4,813
50	Study design biases in pancreatic inflammatory diseases. <i>Gut</i> , 2012, 61, 1778-1779.	12.1	2
51	Quantification of Serum Levels of Pepsinogens and Gastrin to Assess Eradication of Helicobacter Pylori. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 440-442.	4.4	23
52	Connections Between Genetics and Clinical Data: Role of MCP-1, CFTR, and SPINK-1 in the Setting of Acute, Acute Recurrent, and Chronic Pancreatitis. <i>American Journal of Gastroenterology</i> , 2010, 105, 199-206.	0.4	61
53	Italian consensus guidelines for chronic pancreatitis. <i>Digestive and Liver Disease</i> , 2010, 42, S381-S406.	0.9	140
54	Chronic pancreatitis: Report from a multicenter Italian survey (PanCroInfAISP) on 893 patients. <i>Digestive and Liver Disease</i> , 2009, 41, 311-317.	0.9	136

#	ARTICLE	IF	CITATIONS
55	Clinical and Radiological Outcome of Patients Suffering From Chronic Pancreatitis Associated With Gene Mutations. <i>Pancreas</i> , 2008, 37, 371-376.	1.1	5
56	Usefulness of a Serological Panel Test in the Assessment of Gastritis in Symptomatic Children. <i>Digestive Diseases</i> , 2007, 25, 206-213.	1.9	31
57	Quality of Life in Uncomplicated Symptomatic Diverticular Disease: Is It Another Good Reason for Treatment?. <i>Digestive Diseases</i> , 2007, 25, 252-259.	1.9	72
58	AORTO-DUODENAL FISTULA: MULTIDETECTOR COMPUTED TOMOGRAPHY AND GASTRODUODENOSCOPY FINDINGS OF A RARE CAUSE OF UPPER GASTROINTESTINAL HEMORRHAGE. <i>Digestive Endoscopy</i> , 2007, 19, 153-154.	2.3	1
59	A Curcumin-Based 1-Week Triple Therapy for Eradication of <i>Helicobacter pylori</i> Infection: Something to Learn From Failure?. <i>Helicobacter</i> , 2007, 12, 238-243.	3.5	111
60	Protective effects of proton pump inhibitors against indomethacin-induced lesions in the rat small intestine. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2007, 374, 283-291.	3.0	33
61	Prevention of Complications and Symptomatic Recurrences in Diverticular Disease with Mesalazine: A 12-Month Follow-up. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2934-2941.	2.3	74
62	Are there useful biomarkers for gastric cancer?. <i>Digestive and Liver Disease</i> , 2006, 38, 308-309.	0.9	6
63	Use of Mesalazine in Diverticular Disease. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, S155-S159.	2.2	30
64	Bovine lactoferrin for <i>Helicobacter pylori</i> eradication: an open, randomized, multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1235-1240.	3.7	43
65	A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. <i>Nature Genetics</i> , 2006, 38, 668-673.	21.4	220
66	Usefulness of Serum Pepsinogens in <i>Helicobacter pylori</i> Chronic Gastritis: Relationship With Inflammation, Activity, and Density of the Bacterium. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1791-1795.	2.3	50
67	Does <i>Helicobacter pylori</i> infection eradication modify peptic ulcer prevalence A 10 years' endoscopic survey. <i>World Journal of Gastroenterology</i> , 2006, 12, 2398.	3.3	33
68	Effects of chronic therapy with non-steroidal antiinflammatory drugs on gastric permeability of sucrose: A study on 71 patients with rheumatoid arthritis. <i>World Journal of Gastroenterology</i> , 2006, 12, 5017.	3.3	3
69	Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels. <i>Fundamental and Clinical Pharmacology</i> , 2005, 19, 497-501.	1.9	28
70	Recovery of gastric function after <i>Helicobacter pylori</i> eradication in subjects with body atrophic gastritis: Prospective 4-year study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1661-1666.	2.8	6
71	Efficacy of Mesalazine in the Treatment of Symptomatic Diverticular Disease. <i>Digestive Diseases and Sciences</i> , 2005, 50, 581-586.	2.3	102
72	Natural Course of Functional Dyspepsia After <i>Helicobacter pylori</i> Eradication: A Seven-Year Survey. <i>Digestive Diseases and Sciences</i> , 2005, 50, 2286-2295.	2.3	16

#	ARTICLE	IF	CITATIONS
73	Quality of life in patients with chronic pancreatitis. <i>Digestive and Liver Disease</i> , 2005, 37, 181-189.	0.9	81
74	Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti- <i>Helicobacter pylori</i> antibodies in the management of dyspeptic patients in primary care. <i>Digestive and Liver Disease</i> , 2005, 37, 501-508.	0.9	63
75	The quality of life in patients with chronic pancreatitis evaluated using the SF-12 questionnaire: A comparative study with the SF-36 questionnaire. <i>Digestive and Liver Disease</i> , 2005, 38, 109-115.	0.9	52
76	Genetics of chronic pancreatitis. <i>JOP: Journal of the Pancreas</i> , 2005, 6, 53-9.	1.5	1
77	Clinical Usefulness of Serum Pepsinogen II in the Management of <i>Helicobacter pylori</i> Infection. <i>Digestion</i> , 2004, 70, 167-172.	2.3	21
78	Early Epigastric Pain After PPI Administration: Exacerbation of <i>Helicobacter pylori</i> Corpus Gastritis?. <i>Helicobacter</i> , 2004, 9, 92-94.	3.5	4
79	The size of pancreatic pseudocyst does not influence the outcome of invasive treatments. <i>Digestive and Liver Disease</i> , 2004, 36, 135-140.	0.9	29
80	Rabeprazole in a one-week eradication therapy of <i>Helicobacter pylori</i> : Comparison of different dosages. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 783-786.	2.8	8
81	Association of keratin 8 gene mutation with chronic pancreatitis. <i>Digestive and Liver Disease</i> , 2003, 35, 416-420.	0.9	42
82	Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a southern European population. <i>Digestive and Liver Disease</i> , 2003, 35, 571-576.	0.9	27
83	Use of bovine lactoferrin for <i>Helicobacter pylori</i> eradication. <i>Digestive and Liver Disease</i> , 2003, 35, 706-710.	0.9	72
84	“Serological biopsy” in first-degree relatives of patients with gastric cancer affected by <i>Helicobacter pylori</i> infection. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 1223-1227.	1.5	37
85	Use of Lactoferrin for <i>Helicobacter pylori</i> Eradication. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, 396-398.	2.2	35
86	Association of HLA-DRB1*0401 Allele with Chronic Pancreatitis. <i>Pancreas</i> , 2003, 26, 388-391.	1.1	14
87	Gastroprotective effects of amlolmetin guacyl: a new non-steroidal anti-inflammatory drug that activates inducible gastric nitric oxide synthase. <i>Digestive and Liver Disease</i> , 2002, 34, 403-410.	0.9	16
88	Macrohematuria Caused by a Fall in Prothrombin Activity as a Clinical Presentation of Celiac Disease. <i>Journal of Clinical Gastroenterology</i> , 2002, 35, 359-360.	2.2	2
89	Hypercalcemia due to ectopic secretion of parathyroid related protein from pancreatic carcinoma: a case report. <i>Acta Biomedica</i> , 2002, 73, 37-40.	0.3	3
90	Progressive familial intrahepatic cholestasis. <i>Acta Biomedica</i> , 2002, 73, 53-6.	0.3	8

#	ARTICLE	IF	CITATIONS
91	Lactoferrin: mechanism of action, clinical significance and therapeutic relevance. Acta Biomedica, 2002, 73, 71-3.	0.3	10
92	Hyperbilirubinemia: Does It Matter?. Canadian Journal of Gastroenterology & Hepatology, 1999, 13, 663-668.	1.7	1